The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.

Anyone at risk of hepatitis B exposure or needing routine screening should undergo this test. This includes individuals with potential exposure through sexual contact, blood transfusions, or needle-sharing.

Yes, the HBSAg Spot Test is highly accurate in detecting hepatitis B surface antigen. However, a positive result requires confirmation through additional tests.

No, additional tests are needed to differentiate between acute and chronic hepatitis B infection.

A positive result indicates possible hepatitis B infection. Further confirmatory tests and counseling will be provided to determine the next steps for treatment and care.

A blood sample is collected from a vein in your arm and then analyzed.

Yes, it can detect elevated blood sugar levels, which may indicate diabetes.

No, this test can be done at any time of the day without fasting.

High levels may suggest diabetes or another metabolic disorder.

Results are usually available on the same day of testing.